Enanta Pharmaceuticals, Inc balance sheet ENTA

Annual Quarterly

As of Jun 30, 2026, Enanta Pharmaceuticals, Inc had total assets of $296.9 million and total liabilities of $195.8 million. Total assets were down 1.4% from a year earlier. Stockholders' equity was $101.1 million. It held $211.5 million in cash and investments against $55.7 million of total debt, net cash of $155.8 million. The current ratio, current assets divided by current liabilities, was 3.76.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Q3 FY2026
Jun 30, 2026
Q2 FY2026
Mar 31, 2026
Q1 FY2026
Dec 31, 2025
Q4 FY2025
Sep 30, 2025
Q3 FY2025
Jun 30, 2025
Q2 FY2025
Mar 31, 2025
Q1 FY2024
Dec 31, 2024
Q4 FY2024
Sep 30, 2024
Assets
Cash
33
-25.4%
35
-42.0%
37
32
-13.3%
45
+25.3%
60
-5.2%
84
+99.8%
37
-56.4%
Short-term investments
156
-2.0%
129
-3.2%
148
157
-25.8%
159
-18.0%
133
-43.8%
132
-23.2%
211
-25.9%
Long-term investments
22
63
56
—
—
—
—
—
Cash and investments
211
+3.6%
227
+17.4%
242
189
-23.9%
204
-25.1%
193
-35.6%
217
-10.2%
248
-32.9%
Receivables
7
-21.6%
8
+15.0%
8
7
+3.6%
8
+1.9%
7
-12.4%
8
-65.8%
7
-22.8%
Total current assets
204
-8.6%
178
-26.5%
199
204
-31.9%
223
-22.3%
243
-30.8%
268
-5.5%
300
-29.1%
Property and equipment, net
32
-12.8%
33
-11.9%
34
35
+8.3%
37
+46.2%
38
+142.7%
37
+330.4%
33
+174.3%
Total assets
297
-1.4%
315
-2.6%
330
281
-25.5%
301
-24.5%
323
-21.9%
349
+0.3%
377
-18.5%
Liabilities and equity
Accounts payable
3
-7.2%
4
-8.3%
2
2
-75.7%
4
-66.8%
5
-29.3%
5
+8.6%
8
+95.3%
Total current liabilities
54
+21.6%
46
+1.1%
45
49
-15.6%
45
-23.5%
46
-15.9%
49
+113.3%
58
-8.4%
Total liabilities
196
-11.7%
198
-13.7%
203
216
-12.8%
222
-11.3%
229
-7.3%
237
+407.2%
248
+0.9%
Stockholders' equity
101
+27.5%
117
+24.6%
127
65
-49.8%
79
-46.8%
94
-43.7%
112
-62.8%
129
-40.6%
Debt
Lease liabilities
56
-4.1%
57
-3.7%
57
58
+4.4%
58
+14.8%
59
+25.0%
57
+126.7%
55
+109.2%
Total debt
56
-4.1%
57
-3.7%
57
58
+4.4%
58
+14.8%
59
+25.0%
57
+126.7%
55
+109.2%
Net cash
156
+6.7%
170
+26.6%
185
131
-32.0%
146
-34.2%
135
-46.8%
159
-26.3%
193
-43.9%
Ratios
Current ratio
3.76x
3.84x
4.44x
4.21x
5.00x
5.29x
5.47x
5.21x
Debt to equity
0.55x
0.48x
0.45x
0.89x
0.73x
0.63x
0.51x
0.43x
Return on equity
-62.56%
-53.17%
—
-126.53%
-116.06%
-103.08%
-113.69%
-90.09%
Return on assets
-21.30%
-19.70%
—
-29.17%
-30.57%
-29.85%
-36.46%
-30.81%
Book value per share
3.47
4.01
4.36
3.03
3.71
4.38
5.24
6.02
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ENTA (Nasdaq)
Fiscal year ends
September 30
Headquarters
Watertown, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1177648

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.